[go: up one dir, main page]

LT3390390T - Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui - Google Patents

Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui

Info

Publication number
LT3390390T
LT3390390T LTEPPCT/US2016/066799T LT16066799T LT3390390T LT 3390390 T LT3390390 T LT 3390390T LT 16066799 T LT16066799 T LT 16066799T LT 3390390 T LT3390390 T LT 3390390T
Authority
LT
Lithuania
Prior art keywords
bipyrazolyle
treatment
autoimmune diseases
derivatives suitable
derivatives
Prior art date
Application number
LTEPPCT/US2016/066799T
Other languages
English (en)
Inventor
Todd Bosanac
Joerg Bentzien
Michael Jason Burke
Ryan Michael FRYER
Eric Thomas LARSON
Wang Mao
Bryan Patrick MCKIBBEN
Yue Shen
Fariba Soleymanzadeh
Matt Aaron Tschantz
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of LT3390390T publication Critical patent/LT3390390T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2016/066799T 2015-12-16 2016-12-15 Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui LT3390390T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268278P 2015-12-16 2015-12-16
US201662431008P 2016-12-07 2016-12-07
PCT/US2016/066799 WO2017106429A2 (en) 2015-12-16 2016-12-15 Heteroaromatic compounds as btk inhibitors

Publications (1)

Publication Number Publication Date
LT3390390T true LT3390390T (lt) 2021-11-25

Family

ID=58737849

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/066799T LT3390390T (lt) 2015-12-16 2016-12-15 Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui

Country Status (30)

Country Link
US (6) US9975882B2 (lt)
EP (1) EP3390390B1 (lt)
JP (1) JP6976947B2 (lt)
KR (1) KR102691112B1 (lt)
CN (1) CN108368086B (lt)
AU (1) AU2016370743B2 (lt)
BR (1) BR112018011969B1 (lt)
CA (1) CA3005268C (lt)
CL (1) CL2018001569A1 (lt)
CO (1) CO2018005954A2 (lt)
CY (1) CY1124749T1 (lt)
DK (1) DK3390390T3 (lt)
EA (1) EA034561B1 (lt)
ES (1) ES2897910T3 (lt)
HR (1) HRP20211845T1 (lt)
HU (1) HUE056877T2 (lt)
IL (1) IL259281B (lt)
LT (1) LT3390390T (lt)
MX (1) MX375471B (lt)
MY (1) MY197440A (lt)
PE (1) PE20181074A1 (lt)
PH (1) PH12018501248B1 (lt)
PL (1) PL3390390T3 (lt)
PT (1) PT3390390T (lt)
RS (1) RS62525B1 (lt)
SA (1) SA518391864B1 (lt)
SG (1) SG11201804890TA (lt)
SI (1) SI3390390T1 (lt)
TW (1) TWI726017B (lt)
WO (1) WO2017106429A2 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
PL3390390T3 (pl) * 2015-12-16 2022-01-24 Boehringer Ingelheim International Gmbh Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych
HUE051921T2 (hu) 2015-12-16 2021-03-29 Loxo Oncology Inc Kináz inhibitorként alkalmas vegyületek
EP3402789B1 (en) 2016-01-13 2020-03-18 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019027860A1 (en) * 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh INTERMEDIATE COMPOUNDS AND METHODS
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
HUE060872T2 (hu) * 2018-12-03 2023-04-28 Boehringer Ingelheim Int Heteroaromás vegyületek mint vanin-inhibitorok
CA3120037A1 (en) * 2018-12-03 2020-06-11 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as vanin inhibitors
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子
LT3972603T (lt) * 2019-05-23 2024-12-10 Novartis Ag Sjogreno sindromo gydymo būdai naudojant brutono tirozino kinazės inhibitorių
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors
AU2022409472A1 (en) 2021-12-14 2024-06-27 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
CA2369076A1 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
HRP20040098B1 (en) 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
EP1436265A4 (en) * 2001-09-27 2004-12-15 Smithkline Beecham Corp CHEMICALS
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
WO2007117692A2 (en) 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
BRPI0810086B1 (pt) 2007-03-28 2021-11-09 Pharmacyclics Llc Composto inibidor de tirosina quinase de bruton, uso do referido composto e composição farmacêutica
AU2009275988B2 (en) 2008-07-29 2014-03-27 Universite De Liege A genetic marker test for Brachyspina and fertility in cattle
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
CN102639513A (zh) 2009-12-17 2012-08-15 默克专利有限公司 鞘氨醇激酶抑制剂
CN102918040B (zh) 2010-05-31 2015-03-18 小野药品工业株式会社 6-羟基嘌呤衍生物
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ, インコーポレイテッド ヘテロアリールおよびその使用
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013113097A1 (en) 2012-01-31 2013-08-08 Beta Pharma Canada Inc. Cyclic molecules as bruton's tyrosine kinase inhibitors
EP2882741B1 (en) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CA2888960C (en) 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2970163B1 (en) * 2013-03-14 2018-02-28 Boehringer Ingelheim International GmbH 5-thiazolecarboxamide dervatives and their use as btk inhibitors
EP3099674B1 (en) 2014-01-29 2018-10-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
PL3390390T3 (pl) * 2015-12-16 2022-01-24 Boehringer Ingelheim International Gmbh Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych

Also Published As

Publication number Publication date
US20190092759A1 (en) 2019-03-28
JP6976947B2 (ja) 2021-12-08
CO2018005954A2 (es) 2018-07-10
PL3390390T3 (pl) 2022-01-24
SI3390390T1 (sl) 2021-12-31
PE20181074A1 (es) 2018-07-04
US20180222893A1 (en) 2018-08-09
EP3390390B1 (en) 2021-09-01
HUE056877T2 (hu) 2022-03-28
PT3390390T (pt) 2021-11-18
WO2017106429A2 (en) 2017-06-22
AU2016370743B2 (en) 2020-11-26
US9975882B2 (en) 2018-05-22
SA518391864B1 (ar) 2021-12-13
MY197440A (en) 2023-06-19
PH12018501248B1 (en) 2023-03-10
BR112018011969B1 (pt) 2023-02-23
SG11201804890TA (en) 2018-07-30
CY1124749T1 (el) 2022-07-22
JP2019505491A (ja) 2019-02-28
MX2018007333A (es) 2018-08-24
TW201731838A (zh) 2017-09-16
HRP20211845T1 (hr) 2022-03-04
CA3005268C (en) 2024-04-30
KR102691112B1 (ko) 2024-08-05
KR20180095655A (ko) 2018-08-27
MX375471B (es) 2025-03-06
RS62525B1 (sr) 2021-11-30
BR112018011969A2 (pt) 2018-12-04
IL259281B (en) 2021-04-29
US20210009567A1 (en) 2021-01-14
US20180030037A1 (en) 2018-02-01
EA201891399A1 (ru) 2019-01-31
IL259281A (en) 2018-07-31
EA034561B1 (ru) 2020-02-20
PH12018501248A1 (en) 2019-01-28
CN108368086B (zh) 2021-01-08
CN108368086A (zh) 2018-08-03
CA3005268A1 (en) 2017-06-22
EP3390390A2 (en) 2018-10-24
US20200055843A1 (en) 2020-02-20
CL2018001569A1 (es) 2018-10-05
WO2017106429A3 (en) 2017-08-17
HK1256795A1 (en) 2019-10-04
US20170174663A1 (en) 2017-06-22
TWI726017B (zh) 2021-05-01
ES2897910T3 (es) 2022-03-03
AU2016370743A1 (en) 2018-05-24
DK3390390T3 (da) 2021-12-06

Similar Documents

Publication Publication Date Title
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
IL269371A (en) Treatment methods
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
LT3169328T (lt) Chinolino dariniai, skirti uždegiminių ligų gydymui
HUE059694T2 (hu) Készítmény rák kezelésére
EP3291824C0 (en) ANTIMICROBIAL THERAPY
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
HUE059158T2 (hu) Eljárás pridopidin elõállítására
LT3609529T (lt) Rnr, skirta autoimuninių ligų gydymui
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
LT3353177T (lt) Tricikliniai heterociklai, skirti vėžio gydymui
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
IL246721B (en) History of 5-benzylisoquinoline for the treatment of cardiovascular diseases
LT3153511T (lt) 2-acilaminotiazolo dariniai, skirti panaudoti šlapimo pūslės/šlapimo takų ligų prevencijai arba gydymui
HUE064604T2 (hu) Menotropin meddõség kezelésére
LT3113778T (lt) Piridazino dariniai, skirti naudoti ataksinio sutrikimo profilaktikai arba gydymui
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
LT3273957T (lt) Biotinas, skirtas demielinizuojančių neuropatijų gydymui
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme
HUE063820T2 (hu) Módszerek kardiovaszkuláris betegségek kezelésére
IL259381B (en) Mirabegron for the treatment of retinal diseases